Organon: 7% Yield, 4x P/E, Big Upside Potential
Organon is a strong investment opportunity with a high yield, diversified portfolio, steady performance, and transformative ...
Seeking Alpha1d
Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade)
In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the ...
GlobalData on MSN15d
Dermavant acquisition expands Organon’s dermatology portfolio
Organon has completed the acquisition of Dermavant Sciences, a subsidiary of Roivant, expanding its dermatology portfolio.
Nasdaq17d
Organon completes acquisition of Dermavant
Organon (OGN) announced completion of its acquisition of Dermavant Sciencesfrom Roivant (ROIV). Dermavant is a company dedicated to developing and commercializing innovative therapeutic solutions ...
Business Insider17d
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
3, 4 “The future of dermatology depends on innovative treatments like VTAMA, and Organon’s acquisition of Dermavant allows us to further expand our existing portfolio of established brands and ...
Pharmaceutical Technology16d
Dermavant acquisition expands Organon’s dermatology portfolio
Organon has completed the acquisition of Dermavant Sciences, a subsidiary of Roivant, expanding its dermatology portfolio.
Stockhouse17d
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
“The future of dermatology depends on innovative treatments like VTAMA, and Organon’s acquisition of Dermavant allows us to further expand our existing portfolio of established brands ...